Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas
| Autor: | W. L. Vervenne, James P. Thomas, Helmut Oettle, N. Enas, G. Spitzer, Muhammad Wasif Saif, A. Weitzman, C. Visseren-Grul, D. A. Richards |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Agonist
chemistry.chemical_classification Cancer Research medicine.medical_specialty business.industry medicine.drug_class Leukotriene B4 receptor Antagonist Peroxisome proliferator-activated receptor Pharmacology medicine.disease Placebo Gemcitabine Endocrinology Oncology chemistry Internal medicine medicine Adenocarcinoma Receptor business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 23:4092-4092 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2005.23.16_suppl.4092 |
| Popis: | 4092 Background: LY293111 (LY) is a novel oral anticancer agent with known leukotriene B4 receptor antagonist and peroxisome proliferator acvtivated receptor [PPAR] gamma agonist properties, that s... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|